Introduction
============

Diabetic retinopathy (DR) is a common blinding complication in patients with type 1 and type 2 diabetes mellitus ([@b1-etm-0-0-6635],[@b2-etm-0-0-6635]). Proliferative DR (PDR) is a more serious stage of DR, which is characterized by neovascularization on the surface of the retina or the optic disc ([@b3-etm-0-0-6635]). The newly-formed vessels are prone to hemorrhaging, which threatens the vision of the sufferer and eventually culminates in blindness. PDR is associated with environmental and genetic factors. The length of time patients have suffered with diabetes, glycemic control, hypertension, and other environmental factors are well-established risk factors of PDR ([@b4-etm-0-0-6635]). Genetic variations may explain some of the heterogeneity in the development of PDR. Several candidate genes have been implicated in the pathogenesis of PDR in patients with type 2 diabetes ([@b5-etm-0-0-6635]). For example, vascular endothelial growth factor (VEGF) was found to be overexpressed in fibrovascular membranes (FVMs) in patients with PDR, suggesting that it may contribute to the development of PDR ([@b6-etm-0-0-6635]). Gene polymorphisms of other growth factors, including basic fibroblast growth factor and insulin-like growth factor have also been shown to be important in the pathogenesis of PDR ([@b7-etm-0-0-6635],[@b8-etm-0-0-6635]). The association between single-nucleotide polymorphisms of oxidative stress genes and PDR in type 2 diabetes has been reported in a number of previous studies, including manganese superoxide dismutase, catalase myeloperoxidase, glutathione S-transferase, NADPH oxidase, endothelial nitric oxide synthase and inducible nitric oxide synthase ([@b9-etm-0-0-6635]--[@b11-etm-0-0-6635]).

However, the exact pathogenesis of PDR remains to be elucidated. At present, an increasing number of gene expression profiling studies have been performed to reveal the genetic mechanisms of PDR ([@b3-etm-0-0-6635],[@b12-etm-0-0-6635],[@b13-etm-0-0-6635]). The transcriptomics datasets using the platforms of microarrays or RNA-sequencing are available in public databases, including the functional genomics data repository of Gene Expression Omnibus (GEO) and Sequence Read Archive ([@b14-etm-0-0-6635]). In the present study, microarray datasets of gene expression in FVMs excised from patients with proliferative diabetic retinopathy were utilized to comprehensively analyze the molecular expression patterns of PDR.

Materials and methods
=====================

### Microarray data collection and preprocessing

In order to investigate the regulatory mechanisms of PDR at the transcriptomic level, gene expression profiling datasets were retrieved from the GEO. Finally, the raw data of GSE60436 contributed by Ishikawa *et al*, which is the gene expression profile of FVMs associated with PDR, was selected and downloaded ([@b3-etm-0-0-6635]). In this array, there were a total of nine RNA samples. Of these, three control RNA samples were from the human retina obtained from Clontech Laboratories, Inc. (Mountainview, CA, USA), and six RNA samples were obtained from the retinal surface with horizontal scissors of patients with PDR undergoing pars plana vitrectomy, and were classified into active and inactive samples according to the clinical findings of neovascularization (NV) in the FVMs, with three samples per group. The active FVMs represent samples with the presence of NV in the membranes, and the inactive FVMs represent samples with an absence of NV in the membranes. The Illumina HumanWG-6 v3.0 Expression BeadChip (GPL6884; Illumina, Inc., San Diego, CA, USA) platform was used to screen PDR-associated genes. The data preprocessing was performed by R v3.2.2 (<https://www.r-project.org/>). The Robust Multichip Average algorithm in the oligo package was used to normalize the raw expression data and generate normalized gene expression intensity ([@b15-etm-0-0-6635]).

### Differentially expressed gene (DEG) analysis

The analysis of DEGs was performed using R v3.2.2 and Bioconductor libraries (<http://www.bioconductor.org/>). The empirical Bayes algorithm (function 'eBayes') within the Limma package was used to detect DEGs between the case samples, including the active or inactive samples and the controls. Upregulated genes were considered as a logarithmic transformed fold-change log2(FC) ≥1 and a false discovery rate (FDR) adjusted P-value ≤0.05. Downregulated genes were considered as log2(FC) ≤-1 and an FDR P-value ≤0.05. Differential expression analysis in the two comparisons for the active and inactive FVMs were performed.

### Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analysis

The Database for Annotation, Visualization, and Integrated Discovery Bioinformatics Resource 6.7 (<https://david.ncifcrf.gov/>) was used to perform KEGG pathway enrichment analysis ([@b16-etm-0-0-6635]). The inputs were utilized from the list of DEGs. An enriched pathway where P\<0.05 was considered to indicate a statistically significant difference. InteractiVenn (<http://www.interactivenn.net/>) was utilized to draw a Venn diagram in order to illustrate the overlapping genes or pathways between active and inactive regulation.

### Targeted genes by transcription factor (TF) analysis

The union set of the differentially expressed target genes in total and the subgroups was obtained and IneractiVenn software was used to illustrate the results. TF analysis was performed by integrating the database of TRANSFAC^®^ 7.0 (<http://genexplain.com/transfac/>), which provides data on eukaryotic TFs, their experimentally-proven binding sites, consensus binding sequences (positional weight matrices), and regulated genes ([@b17-etm-0-0-6635],[@b18-etm-0-0-6635]).

Results and Discussion
======================

### DEGs associated with PDR

Based on the analysis of DEGs compared with the control samples, the significant genes associated with active FVMs and inactive FVMs were identified ([Fig. 1](#f1-etm-0-0-6635){ref-type="fig"}). There were a total of 2,480 significantly dysregulated genes, including 690 upregulated and 1,790 downregulated genes, identified in the active FVMs. Furthermore, for the inactive FVMs a total of 2,369 genes were identified as significantly dysregulated, including 503 upregulated and 1,866 downregulated genes ([Fig. 1A-C](#f1-etm-0-0-6635){ref-type="fig"}). According to the comparison of significant genes in each group, a total of 1,838 overlapping genes were identified as significant in active and inactive FVMs, comprising 642 specific genes for active FVMs and 531 specific genes for inactive FVMs. Among the overlapping genes, there were a total of 1,505 commonly downregulated genes and 332 commonly upregulated genes ([Fig. 1D](#f1-etm-0-0-6635){ref-type="fig"}). Only one gene, flavin-containing monooxygenase isoform 2 (FMO2), was significantly downregulated (logFC=−1.44, P=0.00743) in the active FVMs but significantly upregulated (logFC=1.28, P=0.000986) in the inactive FVMs ([Fig. 1E](#f1-etm-0-0-6635){ref-type="fig"}). FMO2 has been reported to exhibit catalytic functions in a diverse range of species ([@b19-etm-0-0-6635],[@b20-etm-0-0-6635]). In previous studies, the activation of FMO2 has been reported as necessary for dietary restriction-mediated life-span extension, and has also been reported as a biomarker for a starvation-associated longevity response in *Caenorhabditis elegans* ([@b21-etm-0-0-6635],[@b22-etm-0-0-6635]).

### Functional enrichment associated with PDR

In order to annotate the functions of significant gene sets associated with PDR, KEGG pathway enrichment analysis was performed in each group of DEGs. In total, there were 24 significantly associated pathways in the active FVMs and 23 significantly associated pathways in the inactive FVMs, including 10 overlapping pathways ([Fig. 2A](#f2-etm-0-0-6635){ref-type="fig"}). For the upregulated genes in the active FVMs, the top 10 pathways were extracellular matrix (ECM)-receptor interaction, focal adhesion, protein digestion and absorption, amoebiasis, leishmaniasis, small cell lung cancer, rheumatoid arthritis, cytokine-cytokine receptor interaction, pathways in cancer, and leukocyte transendothelial migration; for downregulated genes in the active FVMs, the top 10 pathways were metabolic pathways, tyrosine metabolism, arginine and proline metabolism, phototransduction, phenylalanine metabolism, β-alanine metabolism, proximal tubule bicarbonate reclamation, calcium signaling pathway, tryptophan metabolism, and histidine metabolism ([Fig. 2B](#f2-etm-0-0-6635){ref-type="fig"}). By contrast, the top 10 pathways for upregulated genes in the inactive FVMs were ECM-receptor interaction, rheumatoid arthritis, cell adhesion molecules (CAMs), *Staphylococcus aureus* infection, graft-vs.-host disease, focal adhesion, asthma, intestinal immune network for IgA production, amoebiasis, and type I diabetes mellitus. The top 10 pathways for downregulated genes in the inactive FVMs were metabolic pathways, phototransduction, arginine and proline metabolism, Alzheimer\'s disease, Parkinson\'s disease, proximal tubule bicarbonate reclamation, cardiac muscle contraction, oxidative phosphorylation, Huntington\'s disease, and phenylalanine metabolism ([Fig. 2C](#f2-etm-0-0-6635){ref-type="fig"}). The details of associated genes in these top 10 pathways in active and inactive FVMs are presented in [Tables I](#tI-etm-0-0-6635){ref-type="table"} and [II](#tII-etm-0-0-6635){ref-type="table"}.

### TFs regulating target genes associated with PDR

By integrating the target genes identified in the present study with the gene regulation data from TRANSFAC, several associated TFs were identified for the active and inactive FVMs, respectively. As a result, a total of 118 TFs were identified for the active FVMs, including 26 upregulated TFs and 92 downregulated TFs. For the inactive FVMs, a 103 total TFs were identified, including 20 upregulated and 83 downregulated TFs. According to the aforementioned data comparison, there were 78 overlapping TFs, including eight commonly upregulated and 70 commonly downregulated TFs ([Fig. 3A](#f3-etm-0-0-6635){ref-type="fig"}). Among these, the transcription factor lymphoid enhancing binding factor-1 (LEF1) was identified as an important regulator. LEF1 is reported to be a central regulator of effecting the differentiation and cell number of invariant natural killer T cells ([@b23-etm-0-0-6635]). It has been revealed that the Wnt/β-catenin effector LEF1 may regulate tyrosinase gene transcription during melanocyte development and differentiation ([@b24-etm-0-0-6635]). In the present study, LEF1 was upregulated in active and inactive FVMs, with the ability to activate nine target genes, including claudin 2, catenin β1 δ-like 1, microphthalmia-associated transcription factor, matrix metalloproteinase 7, MYC binding protein, neuronal cell adhesion molecule, OCA2 and secreted phosphoprotein 1 (SPP1). However, the transcription of six genes, namely ALX4, CD1D, desmoglein 4, interleukin (IL)13, IL4 and IL5, were repressed by LEF1. The majority of LEF1 target genes had similar expression levels between active and inactive FVMs. However, the expression of SPP1 was significantly higher in the active samples ([Fig. 3B](#f3-etm-0-0-6635){ref-type="fig"}), but was not significantly altered in the inactive samples ([Fig. 3C](#f3-etm-0-0-6635){ref-type="fig"}), when compared with the controls. The co-expression of SPP1 and LEF1 protein was previously investigated by immunohistochemistry using a tFVM microarray, which demonstrated that LEF1 may serve as a prognostic biomarker for primary colorectal carcinoma and liver metastases ([@b25-etm-0-0-6635]). In the present study, it was demonstrated that the Wnt/β-catenin effector LEF1 regulating SPP1 may be important in PDR.

In a previous study based on microarray analysis using Welch\'s t-test coupled with a multidimensional false-discovery control by Ishikawa *et al* ([@b3-etm-0-0-6635]), only 91 genes were identified to be significantly upregulated in active FVMs, the majority of which were clustered in the functional category of angiogenesis. A total of 89 genes were shown to be significantly upregulated in inactive FVMs, the majority of which were clustered in the functional category of metabolism. Furthermore, the ingenuity pathway analysis revealed that ECM-related molecules, including periostin, tenascin C, hexabrachion, transforming growth factor β families, and angiogenic factors, are essential in promoting the development of FVMs associated with PDR. These genetic factors were also identified in the list of upregulated genes in active and inactive FVMs in the present study. A number of previously unreported genes were reidentified, therefore, these results appeared to be more systematic and comprehensive, when compared with those of previous studies. However, due to the lack of relevant molecular biological experimental data in the present study, the identification of genetic site information requires further confirmation in future investigations.
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![Overview of DEGs associated with PDR. (A) Scatter diagram illustrating log2(FC) values of each gene between the active and control samples, including 13,459 upregulated genes and 11,976 downregulated genes. (B) Scatter diagram illustrating log2(FC) values of each gene between the inactive and control samples, including 13,566 upregulated genes and 11,869 downregulated genes. (C) Histogram of the numbers of DEGs in the active and inactive samples. There were 690 upregulated genes and 1,790 downregulated genes identified as significant in the active samples. There were 503 upregulated genes and 1,866 downregulated genes significantly identified in the inactive samples. (D) Venn diagram illustrating the overlapping genes of DEGs in the active and inactive samples. (E) Bar chart of the expression patterns of FMO2 in the active and inactive samples. FMO2 was significantly downregulated (logFC=−1.44, P=0.00743) in the active FVMs but significantly upregulated (logFC=1.28, P=0.000986) in the inactive FVMs. PDR, proliferative diabetic retinopathy; FC, fold change; FVMs, fibrovascular membranes; FMO2, flavin-containing monooxygenase isoform 2; CT, control.](etm-16-04-3539-g00){#f1-etm-0-0-6635}

![Significantly enriched pathways associated with PDR. (A) Venn diagram illustrating the overlapping pathways in the active and inactive samples. (B) Detailed information of the top 10 pathways in the active samples. For 690 upregulated genes in the active FVMs, the top 10 pathways were ECM-receptor interaction, focal adhesion, protein digestion and absorption, amoebiasis, leishmaniasis, small cell lung cancer, rheumatoid arthritis, cytokine-cytokine receptor interaction, pathways in cancer, and leukocyte transendothelial migration; for 1,790 downregulated genes in the active FVMs, the top 10 pathways were metabolic pathways, tyrosine metabolism, arginine and proline metabolism, phototransduction, phenylalanine metabolism, β-alanine metabolism, proximal tubule bicarbonate reclamation, calcium signaling pathway, tryptophan metabolism, and histidine metabolism. (C) Detailed information of the top 10 pathways in the inactive samples. For 503 upregulated genes in the active FVMs, the top 10 pathways were ECM-receptor interaction, focal adhesion, protein digestion and absorption, amoebiasis, leishmaniasis, small cell lung cancer, rheumatoid arthritis, cytokine-cytokine receptor interaction, pathways in cancer, and leukocyte transendothelial migration; for 1,866 downregulated genes in the active FVMs, the top 10 pathways were metabolic pathways, tyrosine metabolism, arginine and proline metabolism, phototransduction, phenylalanine metabolism, β-alanine metabolism, proximal tubule bicarbonate reclamation, calcium signaling pathway, tryptophan metabolism, and histidine metabolism. PDR, proliferative diabetic retinopathy; FVMs, fibrovascular membranes; Up, upregulated; Down, downregulated; ECM, extracellular matrix.](etm-16-04-3539-g01){#f2-etm-0-0-6635}

![Transcription factors associated with proliferative diabetic retinopathy. (A) Venn diagram illustrating the overlapping key TFs in the active and inactive samples. (B) Regulatory model of LEF1 in the active samples, including the regulation types of activation, repression, and unknown. (C) Regulatory model of LEF1 in the inactive samples, including the regulation types of activation, repression, and unknown. TFs, transcription factors; LEF1, lymphoid enhancing binding factor-1.](etm-16-04-3539-g02){#f3-etm-0-0-6635}

###### 

Top 10 upregulated pathways in active fibrovascular membranes.

  Term                                     P-value    n    Gene symbols
  ---------------------------------------- ---------- ---- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ECM-receptor interaction                 6.88E-20   29   CD36, COL1A1, COL1A2, COL3A1, COL4A1, COL4A2, COL5A1, COL5A2, COL6A1, COL6A2, COL6A3, FN1, HMMR, HSPG2, TNC, ITGA1, ITGA2, ITGA4, ITGA5, ITGB1, LAMA4, LAMB1, LAMC1, SPP1, THBS1, THBS2, ITGA11, COL5A3, AGRN
  Focal adhesion                           2.86E-15   37   ACTN1, BIRC2, CCND1, CAV1, COL1A1, COL1A2, COL3A1, COL4A1, COL4A2, COL5A1, COL5A2, COL6A1, COL6A2, COL6A3, DOCK1, FN1, TNC, ITGA1, ITGA2, ITGA4, ITGA5, ITGB1, LAMA4, LAMB1, LAMC1, PDGFB, PDGFRB, PGF, SPP1, THBS1, THBS2, VEGFC, ZYX, ITGA11, COL5A3, PARVG, MYLK2,
  Protein digestion and absorption         1.23E-07   16   COL1A1, COL1A2, COL3A1, COL4A1, COL4A2, COL5A1, COL5A2, COL6A1, COL6A2, COL6A3, COL12A1, COL15A1, SLC1A5, COL5A3, COL18A1, SLC36A1
  Amoebiasis                               1.13E-06   17   ACTN1, COL1A1, COL1A2, COL3A1, COL4A1, COL4A2, COL5A1, COL5A2, FN1, IL1B, LAMA4, LAMB1, LAMC1, PLCB2 TGFB3 TNF, COL5A3
  Leishmaniasis                            3.00E-05   12   CYBA, FCGR1A, HLA-DMB, HLA-DOA, HLA-DQA1, IL1B, ITGA4, ITGB1, STAT1, TGFB3, TNF, MARCKSL1
  Small cell lung cancer                   3.61E-05   13   BIRC2, CCND1, CDK6, CDKN2B, COL4A1, COL4A2, E2F2, FN1, ITGA2, ITGB1, LAMA4, LAMB1, LAMC1
  Rheumatoid arthritis                     7.51E-05   13   CD28, HLA-DMB, HLA-DOA, HLA-DQA1, IL1B, PGF, CCL2, CCL3, CCL3L1, TGFB3, TNF, TNFSF13B, CCL3L3
  Cytokine-cytokine receptor interaction   1.95E-04   24   BMPR2, IL1B, IL2RB, INHBB, CXCL10, CXCL9, TNFRSF11B, PDGFB, PDGFRB, CCL2, CCL3 CCL3L1, CCL8, TGFB3, TNF, TNFSF4, TNFRSF4, VEGFC, TNFRSF10D, TNFSF13B, TNFRSF21, TNFRSF12A, CCL4L1, CCL3L3
  Pathways in cancer                       7.78E-04   26   BIRC2, BIRC5, CCND1, RUNX1, CDK6, CDKN2B, COL4A1, COL4A2, E2F2, ETS1, FN1, ITGA2, ITGB1, LAMA4, LAMB1, LAMC1, MMP9, PDGFB, PDGFRB, PGF, RALA, STAT1, TGFB3, HSP90B1, VEGFC, LEF1
  Leukocyte transendothelial migration     8.65E-04   13   ACTN1, CDH5, CYBA, CYBB, ITGA4, ITGB1, MMP9, MSN, PECAM1, THY1, CLDN5, CLDN1, ESAM

###### 

Top 10 upregulated pathways in inactive fibrovascular membranes.

  Term                                           P-value    n    Gene symbols
  ---------------------------------------------- ---------- ---- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ECM-receptor interaction                       1.52E-13   21   COL1A1, COL1A2, COL3A1, COL4A1, COL4A2, COL5A1, COL5A2, COL6A1, COL6A3, COL11A1, COMP, TNC, ITGA1, ITGA2, ITGA5, LAMA4, LAMB1, LAMC1, THBS1, THBS2, ITGA11
  Rheumatoid arthritis                           6.31E-12   20   CD86, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB4, IL1B, IL6, ITGAL, PGF, CCL2, CCL3, CCL3L1, CCL5, TNF, TNFSF13B, CCL3L3
  Cell adhesion molecules (CAMs)                 1.31E-09   21   CD2, CD6, CD8A, CD86, CD58, CDH2, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB4, ITGAL, NRCAM, CLDN11, PECAM1, CLDN5, CLDN1, ICOS
  *Staphylococcus aureus* infection              1.34E-09   14   C3AR1, C5AR1, FCGR1A, CFH, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB4, CFI, ITGAL
  Graft-vs.-host disease                         3.67E-09   12   CD86, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB4, IL1B, IL6, TNF
  Focal adhesion                                 4.98E-09   25   ACTN1, COL1A1, COL1A2, COL3A1, COL4A1, COL4A2, COL5A1, COL5A2, COL6A1, COL6A3, COL11A1 COMP, TNC, ITGA1, ITGA2, ITGA5 LAMA4, LAMB1, LAMC1, PGF, RAC2, THBS1, THBS2, ITGA11, PARVG
  Asthma                                         1.89E-08   10   FCER1G, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB4, TNF
  Intestinal immune network for IgA production   2.65E-08   12   CD86, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB4, IL6, TNFSF13B, ICOS
  Amoebiasis                                     4.21E-08   17   ACTN1, CD14 COL1A1, COL1A2, COL3A1, COL4A1, COL4A2, COL5A1, COL5A2, COL11A1, IL1B, IL6, LAMA4, LAMB1, LAMC1, PLCB2, TNF
  Type I diabetes mellitus                       7.95E-08   11   CD86, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB4, IL1B, TNF
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